Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...

The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health ...

In addition to presenting 30 abstracts with data on prurigo nodularis, atopic dermatitis, sensitive skin and acne, Galderma will host a series of events dedicated to addressing the real needs of ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.